These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16890831)

  • 1. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.
    May MT; Sterne JA; Costagliola D; Sabin CA; Phillips AN; Justice AC; Dabis F; Gill J; Lundgren J; Hogg RS; de Wolf F; Fätkenheuer G; Staszewski S; d'Arminio Monforte A; Egger M;
    Lancet; 2006 Aug; 368(9534):451-8. PubMed ID: 16890831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
    Chêne G; Sterne JA; May M; Costagliola D; Ledergerber B; Phillips AN; Dabis F; Lundgren J; D'Arminio Monforte A; de Wolf F; Hogg R; Reiss P; Justice A; Leport C; Staszewski S; Gill J; Fatkenheuer G; Egger ME;
    Lancet; 2003 Aug; 362(9385):679-86. PubMed ID: 12957089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.
    May M; Sterne JA; Sabin C; Costagliola D; Justice AC; Thiébaut R; Gill J; Phillips A; Reiss P; Hogg R; Ledergerber B; D'Arminio Monforte A; Schmeisser N; Staszewski S; Egger M;
    AIDS; 2007 May; 21(9):1185-97. PubMed ID: 17502729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
    Egger M; May M; Chêne G; Phillips AN; Ledergerber B; Dabis F; Costagliola D; D'Arminio Monforte A; de Wolf F; Reiss P; Lundgren JD; Justice AC; Staszewski S; Leport C; Hogg RS; Sabin CA; Gill MJ; Salzberger B; Sterne JA;
    Lancet; 2002 Jul; 360(9327):119-29. PubMed ID: 12126821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients.
    Antiretroviral Therapy Cohort Collaboration
    J Acquir Immune Defic Syndr; 2007 Dec; 46(5):607-15. PubMed ID: 18043315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.
    Braitstein P; Brinkhof MW; Dabis F; Schechter M; Boulle A; Miotti P; Wood R; Laurent C; Sprinz E; Seyler C; Bangsberg DR; Balestre E; Sterne JA; May M; Egger M; ;
    Lancet; 2006 Mar; 367(9513):817-24. PubMed ID: 16530575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
    ; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
    Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
    Paredes R; Mocroft A; Kirk O; Lazzarin A; Barton SE; van Lunzen J; Katzenstein TL; Antunes F; Lundgren JD; Clotet B
    Arch Intern Med; 2000 Apr; 160(8):1123-32. PubMed ID: 10789605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies.
    Trickey A; Sabin CA; Burkholder G; Crane H; d'Arminio Monforte A; Egger M; Gill MJ; Grabar S; Guest JL; Jarrin I; Lampe FC; Obel N; Reyes JM; Stephan C; Sterling TR; Teira R; Touloumi G; Wasmuth JC; Wit F; Wittkop L; Zangerle R; Silverberg MJ; Justice A; Sterne JAC
    Lancet HIV; 2023 May; 10(5):e295-e307. PubMed ID: 36958365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.
    Waters L; Fisher M; Anderson J; Wood C; Delpech V; Hill T; Walsh J; Orkin C; Bansi L; Gompels M; Phillips A; Johnson M; Gilson R; Easterbrook P; Leen C; Porter K; Gazzard B; Sabin C;
    HIV Med; 2011 May; 12(5):289-98. PubMed ID: 21054749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.
    Writing Committee for the CASCADE Collaboration
    Arch Intern Med; 2011 Sep; 171(17):1560-9. PubMed ID: 21949165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.
    Melekhin VV; Shepherd BE; Jenkins CA; Stinnette SE; Rebeiro PF; Bebawy SS; Rasbach DA; Hulgan T; Sterling TR
    AIDS Patient Care STDS; 2010 May; 24(5):279-86. PubMed ID: 20438375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
    Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
    PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.
    Li X; Margolick JB; Jamieson BD; Rinaldo CR; Phair JP; Jacobson LP
    J Acquir Immune Defic Syndr; 2011 Aug; 57(5):421-8. PubMed ID: 21602699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
    Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
    Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.
    Thorsteinsson K; Ladelund S; Jensen-Fangel S; Johansen IS; Katzenstein TL; Pedersen G; Storgaard M; Obel N; Lebech AM
    BMC Infect Dis; 2012 Nov; 12():293. PubMed ID: 23140254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand.
    Fregonese F; Collins IJ; Jourdain G; Lecoeur S; Cressey TR; Ngo-Giang-Houng N; Banchongkit S; Chutanunta A; Techapornroong M; Lallemant M;
    J Acquir Immune Defic Syndr; 2012 May; 60(1):91-8. PubMed ID: 22293548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.